/Investor DB

Apollo Health Ventures — 2019 Investments

2 investments dated 2019 · listed companies and verified rows first · show all

Aeovian Pharmaceuticalsaeovian.comSeries A · Oct 2019 · $37M

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.

BiotechBerkeley, US

Allison J. Hulme(CEO & President)inJohn Kincaid(Chief Scientific Officer)inDavis Ryman(Executive Officer)inMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)

Co-investorsCoastCapCTI Life Sciences Fund L.P.Felix JahnFJ LabsLuma GroupSofinnova Ventures+2 more

Tacalyxtacalyx.comSeed · Sep 2019 · $8M

Tacalyx develops novel anticancer therapeutics that target Tumor-Associated Carbohydrate Antigens (TACAs), including antibody-drug conjugate programs.

BiotechDeep TechMedical DevicesBerlin, DE

Peter Seeberger(Co-founder (Prof. Dr.))Oren Moscovitz(CSO & Co-founder)

Co-investorsCreathor VenturesKurma PartnersBoehringer Ingelheim Venture FundThuja Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.